Ovid Therapeutics Inc. (OVID) shares nosedived as the trials missed targets
Hasnain R
December 2, 2020
Ovid Therapeutics Inc. (NASDAQ: OVID) stock plunged 49.77% to 3.34 in the after-market session following the biotech corporation dedicated to developing therapies that change the lives of